Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL) (CRC027)

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Januario Castro, M.D., University of California, San Diego
ClinicalTrials.gov Identifier:
NCT01191190
First received: August 26, 2010
Last updated: September 6, 2013
Last verified: September 2013
  Purpose

Patients who have relapsed/refractory CLL and require therapy as per iwCLL guidelines will be eligible. Subjects will receive a treatment with ofatumumab and HDMP for three consecutive 4 week cycles. The primary endpoint is to determine the complete response (CR) to therapy and the secondary endpoints will assess the safety and tolerability of the regimen, the impact of the treatment on progression free, treatment free, overall survival, and pharmacokinetics of ofatumumab. Patients will receive allopurinol for tumor-lysis prophylaxis and antimicrobial prophylaxis.


Condition Intervention Phase
CLL
Drug: Ofatumumab/HDMP
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Ofatumumab in Combination With High-dose Methylprednisolone in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Resource links provided by NLM:


Further study details as provided by University of California, San Diego:

Primary Outcome Measures:
  • IwCLL-WG defined complete remissions [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Adverse events associated with Ofatumumab-HDMP combination regimen. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Progression free, treatment free and overall survival. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • pharmacokinetics of ofatumumab. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Minimal residual disease (MRD) following therapy [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Enrollment: 21
Study Start Date: August 2010
Study Completion Date: August 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ofatumumab/HDMP

High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.

Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered.

Each patient may receive 3 cycles of treatment in the absence of progressive disease or significant toxicity.

Drug: Ofatumumab/HDMP

High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.

Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered based on specific schedule.

Each patient will receive a maximum of 3 cycles (one cycle is 28 days)

Other Names:
  • Arzerra
  • HuMax-CD20

Detailed Description:

Patients who have relapsed/refractory CLL and require therapy as per iwCLL guidelines will be eligible. Subjects will receive a treatment with ofatumumab and HDMP for three consecutive 4 week cycles. The primary endpoint is to determine the complete response (CR) to therapy and the secondary endpoints will assess the safety and tolerability of the regimen, the impact of the treatment on progression free, treatment free, overall survival, and pharmacokinetics of ofatumumab. Cycles 1-3 will be administered without scheduled interruption every 28 days for a total of 12 weeks of therapy. Patients will receive allopurinol for tumor-lysis prophylaxis and antimicrobial prophylaxis. Blood glucose levels will be monitored immediately after HDMP infusion by finger stick glucometry. Two months following completion of treatment a response assessment will occur per iwCLL guidelines. The treatment will be administered as outpatient, and each cycle will be four weeks in duration.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Previously treated patients with a diagnosis of CLL
  2. Previous treatment with any monoclonal antibody or chemotherapy regardless of response as defined by the iwCLL Working Group Guidelines as evidenced by:

    • progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia
    • massive (i.e. at least 6cm below the left costal margin) or progressive or symptomatic splenomegaly
    • massive nodes (i.e. at least 10cm in longest diameter) or progressive or symptomatic lymphadenopathy.
    • progressive lymphocytosis with an increase of more than 50% over a 2-month period or lymphocyte doubling time (LDT) of less than 6 months.
    • autoimmune anemia and/or thrombocytopenia that is poorly responsive to corticosteroids or other standard therapy (See Section 10.2)
  3. Constitutional symptoms, defined as any one or more of the following disease-related symptoms or signs: unintentional weight loss of 10% or more within the previous 6 months significant fatigue (i.e. ECOG PS 2 or worse, inability to work or perform usual activities), fevers higher than 100.5ºF or 38.0ºC for 2 or more weeks without other evidence of infection, night sweats for more than 1 month without evidence of infection
  4. Subjects must be 18 years of age or older, male or female.
  5. ECOG performance status of 0-2.
  6. Subjects must be able to give informed consent.
  7. Females of child bearing potential(FCBP)† must have a negative serum or urine pregnancy test within 10 - 14 days prior to and again within 24 hours of starting treatment and agree to use a medically accepted contraceptive method for the duration of this study.

Exclusion Criteria:

  1. Hepatitis BsAg positive, Hepatitis BcAb positive, and Hepatitis C positive patients.
  2. Known HIV positive patients.
  3. Diabetics.
  4. Patients with uncontrolled Autoimmune Hemolytic Anemia (AIHA) or autoimmune thrombocytopenia (ITP).
  5. Screening laboratory values within these ranges: platelets <50 x 109/L, neutrophils <1.0 x 109/L, creatinine >2.0 times upper normal limit,total bilirubin >1.5 times upper normal limit (unless a known history of Gilbert's disease), ALT >2.5 times upper normal limit (unless due to disease involvement of liver), alkaline phosphatase >2.5 times upper normal limit (unless due to disease involvement of the liver or bone marrow)
  6. Inability to provide informed consent.
  7. Concurrent malignancy (excluding basal and squamous cell skin cancers).
  8. Active fungal, bacterial, and/or viral infection.
  9. History of peptic ulcer disease resulting in GI bleeding within the last 6 months.
  10. Untreated metabolic disorders such as hypothyroidism and Cushing's disease.
  11. History of steroid-induced psychosis.
  12. Estimated life expectancy of less than 3 months by the investigator's best clinical judgment.
  13. Serious medical condition that would render the subject medically unstable.
  14. Women who are pregnant or breast-feeding.
  15. History of Pancreatitis.
  16. History of Diverticulitis.
  17. Patients with known hypersensitivity to ofatumumab or known history of anaphylaxis to Rituximab or alemtuzumab.
  18. Concurrent use of other anti-cancer agents or treatments.
  19. Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01191190

Locations
United States, California
University of California San Diego, Moores Cancer Center
La Jolla, California, United States, 92093
UC San Diego Moores Cancer Center
La Jolla, California, United States, 92093
Sponsors and Collaborators
Januario Castro, M.D.
GlaxoSmithKline
Investigators
Principal Investigator: Januario Castro, MD University of California, San Diego
Principal Investigator: Thomas J Kipps, MD, PhD Director of the CLL Research Consortium and University of California San Diego
  More Information

Additional Information:
Publications:
Responsible Party: Januario Castro, M.D., Principal Investigator, University of California, San Diego
ClinicalTrials.gov Identifier: NCT01191190     History of Changes
Other Study ID Numbers: 100429
Study First Received: August 26, 2010
Last Updated: September 6, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by University of California, San Diego:
Leukemia
Chronic leukemia
Chronic Lymphocytic Leukemia
Relapsed
Refractory

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Neoplasms by Histologic Type
Neoplasms
Leukemia, B-Cell
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Methylprednisolone acetate
Prednisolone acetate
Methylprednisolone
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Agents
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Neuroprotective Agents

ClinicalTrials.gov processed this record on August 28, 2014